The latest ISMP 1 provides a discussion on the safety of the glucagon-like peptide-1 (GLP-1) medications which have been accumulating in the market for treatment of diabetes. ISMP reviewed adverse drug event reports over a 12 month period associated with these medications and pancreatitis, pancreatic cancer and thyroid cancer. ISMP is recommending stronger warnings in prescribing information for these medications.
Also – a good discussion differentiating the quality assurance requirements between compounding pharmacies and manufacturers. The loop hole here is that many compounding pharmacies are acting as manufacturers and not being held to the same standard.Thanks, Scott Padjen